NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Abaloparatide for treating osteoporosis in postmenopausal women ID882

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
 Company Radius Health (abaloparatide) Patient/carer groups Action on Pain Arthritis Action Arthritis & Musculoskeletal Alliance BackCare Black Health Agency for Equality Daisy Network Hysterectomy Association Menopause Charity Menopause Exchange Menopause Matters Menopause UK Pain Concern Pain UK Queermenopause Royal Osteoporosis Society South Asian Health Foundation 	 General All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services Committee
 Specialised Healthcare Alliance The Pain Relief Foundation Women's Health Concern Versus Arthritis Healthcare professional groups British Dietetic Association British Geriatrics Society British Institute of Musculoskeletal Medicine British Institute of Radiology British Menopause Society British Orthopaedic Association British Pain Society British Society of Rehabilitation Medicine 	 Possible comparator companies Accord Healthcare (alendronic acid, ibandronic acid, teriparatide) Accord-UK (raloxifene, risedronate sodium) Amgen (denosumab) Aristo Pharma (risedronate sodium, strontium ranelate) Aspire Pharma (ibandronic acid, raloxifene, risedronate sodium) Atnahs Pharma (ibandronic acid) Aurobindo Pharma - Milpharm (alendronic acid, risedronate sodium) Dr. Reddy's Laboratories (zoledronic acid) Eli Lilly (teriparatide)

Provisional stakeholder list for the evaluation of abaloparatide for treating osteoporosis in postmenopausal women ID882

Issue date: January 2023

Consultees Commentators (no right to submit or appeal) Physiotherapy Pain Association Gedeon Richter (teriparatide) Internis Pharmaceuticals (alendronic Royal College of General Practitioners acid) Royal College of Nursing Mylan (ibandronic acid) Royal College of Pathologists Novartis (zoledronic acid) Royal College of Physicians Organon Pharma (alendronic acid) Royal College of Radiologists Ranbaxy (UK) Limited a Sun Royal Pharmaceutical Society Pharmaceutical Company (zoledronic Royal Society of Medicine acid) Society and the College of Rosemont (alendronic acid) Radiographers Sandoz (risedronate sodium, ibandronic Society for Endocrinology acid) **UK Clinical Pharmacy Association** Seacross Pharmaceuticals (zoledronic acid) Others Teva UK (teriparatide) Department of Health and Social Care Thornton & Ross (teriparatide) NHS England UCB Pharma (romosozumab) Vygoris (raloxifene) Zentiva (ibandronic acid) Relevant research groups Bone Research Society Chronic Pain Policy Coalition Cochrane Gynaecology and Fertility Group Cochrane Metabolic & Endocrine Disorders Group Cochrane Musculoskeletal Group Cochrane UK Genomics England • MRC Clinical Trials Unit National Institute of Health Research Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Provisional stakeholder list for the evaluation of abaloparatide for treating osteoporosis in postmenopausal women ID882

Issue date: January 2023

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Provisional stakeholder list for the evaluation of abaloparatide for treating osteoporosis in postmenopausal women ID882

Issue date: January 2023

¹ Non company consultees are invited to submit statements relevant to the group they are representing.